Table 2.
Prevalence of PN and SPN over time
| Week since parent study entry | CD4 > 350 (cells/μL) | VL ≤ 400 (cp/ml) | All Participants | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Neuropathy % (95% CI) | Symptomatic Neuropathy % (95% CI) | N | Neuropathy % (95% CI) | Symptomatic Neuropathy % (95% CI) | N | Neuropathy % (95% CI) | Symptomatic Neuropathy % (95% CI) | |
| 0 | 23 | 52.2 (30.6, 73.2) | 21.7 (7.5, 43.7) | 0 | - | - | 92 | 57.6 (46.9, 67.9) | 33.7 (24.2, 44.3) |
| 48 | 135 | 47.4 (38.8, 56.2) | 19.3 (13.0, 26.9) | 180 | 47.2 (39.8, 54.8) | 22.2 (16.4, 29.0) | 382 | 50.3 (45.1, 55.4) | 24.6 (20.4, 29.2) |
| 96 | 158 | 54.4 (46.3, 62.4) | 24.7 (18.2, 32.2) | 210 | 56.2 (49.2, 63.0) | 25.2 (19.5, 31.7) | 382 | 57.3 (52.2, 62.3) | 25.9 (21.6, 30.6) |
| 144 | 114 | 51.8 (42.2, 61.2) | 21.1 (14.0, 29.7) | 155 | 55.5 (47.3, 63.5) | 25.2 (18.5, 32.8) | 267 | 52.8 (46.6, 58.9) | 24.0 (19.0, 29.6) |
| 192 | 101 | 54.5 (44.2, 64.4) | 20.8 (13.4, 30.0) | 128 | 53.9 (44.9, 62.8) | 21.9 (15.1, 30.0) | 217 | 52.5 (45.7, 59.3) | 22.1 (16.8, 28.2) |
| 240 | 83 | 43.4 (32.5, 54.7) | 16.9 (9.5, 26.7) | 95 | 56.8 (46.3, 67.0) | 25.3 (16.9, 35.2) | 162 | 52.5 (44.5, 60.4) | 25.3 (18.8, 32.7) |
| 288 | 78 | 47.4 (36.0, 59.1) | 15.4 (8.2, 25.3) | 107 | 44.9 (35.2, 54.8) | 16.8 (10.3, 25.3) | 156 | 50.0 (41.9, 58.1) | 21.8 (15.6, 29.1) |
| 336 | 64 | 39.1 (27.1, 52.1) | 12.5 (5.6, 23.2) | 80 | 45.0 (33.8, 56.5) | 21.3 (12.9, 31.8) | 131 | 49.6 (40.8, 58.5) | 25.2 (18.0, 33.5) |
| 384 | 64 | 48.4 (35.8, 61.3) | 14.1 (6.6, 25.0) | 77 | 50.6 (39.0, 62.2) | 14.3 (7.4, 24.1) | 120 | 54.2 (44.8, 63.3) | 19.2 (12.6, 24.7) |
| 432 | 55 | 43.6 (30.3, 57.7) | 21.8 (11.8, 35.0) | 77 | 42.9 (31.6, 54.6) | 19.5 (11.3, 30.1) | 106 | 50.9 (41.0, 60.8) | 23.6 (15.9, 32.8) |